Table 2

Mean ± SD (n = 6/group) Peff, NWF, and PEGrec,ss in the in situ perfused rat jejunum

ParameterPerfusateNo PretreatmentPretreatment with ART2-aPretreatment with Vehicle2-b
Peff, antipyrine (· 10−4, cm/s)500 ng/ml ART0.56  ± 0.310.93  ± 0.172-c 0.57  ± 0.30
5000 ng/ml ART0.49  ± 0.210.68  ± 0.380.69  ± 0.29
500 ng/ml ART + inhibitor2-d 0.87  ± 0.180.52  ± 0.180.81  ± 0.24
Peff, d-glucose (· 10−4, cm/s)500 ng/ml ART1.05  ± 0.071.20  ± 0.192-c 0.95  ± 0.16
5000 ng/ml ART0.94  ± 0.160.90  ± 0.240.96  ± 0.26
500 ng/ml ART + inhibitor2-d 1.04  ± 0.240.96  ± 0.200.97  ± 0.23
NWF (ml/h/cm)2-e 500 ng/ml ART−0.09  ± 0.03−0.13  ± 0.052-c −0.12  ± 0.05
5000 ng/ml ART−0.02  ± 0.02−0.04  ± 0.05−0.05  ± 0.06
500 ng/ml ART + inhibitor2-d −0.05  ± 0.03−0.11  ± 0.03−0.12  ± 0.05
PEGrec, ss(%)2-f 500 ng/ml ART102  ± 3110  ± 62-c 106  ± 2
5000 ng/ml ART99.3  ± 398.3  ± 9101  ± 7
500 ng/ml ART + inhibitor2-d 98.2  ± 5107  ± 4107  ± 7

  • ART, artemisinin.

  • ↵2-a Artemisinin emulsion, 60 mg/kg/day orally for 5 days.

  • ↵2-b Vehicle, 10 ml/kg/day orally for 5 days.

  • ↵2-c n = 5.

  • ↵2-d 400 μg/ml R,S-verapamil.

  • ↵2-e p < .001 between 500 ng/ml ART and 5000 ng/ml ART.

  • ↵2-f p < .01 between 500 ng/ml ART and 5000 ng/ml ART.